Aldeyra Therapeutics, Inc.
ALDX
$1.52
-$0.03-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.05M | -27.37M | -33.85M | -43.19M | -50.62M |
| Total Depreciation and Amortization | 266.10K | 257.70K | 252.00K | 251.30K | 250.60K |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 267.30K | 267.30K | 267.30K |
| Total Other Non-Cash Items | 4.17M | 2.34M | 5.16M | 4.91M | 5.30M |
| Change in Net Operating Assets | -3.40M | -1.22M | -5.18M | -2.31M | 3.77M |
| Cash from Operations | -22.02M | -25.99M | -33.35M | -40.08M | -41.04M |
| Capital Expenditure | -23.10K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.00M | 40.45M | 47.74M | 30.17M | 10.44M |
| Cash from Investing | 40.98M | 40.45M | 47.74M | 30.17M | 10.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -15.30M | -- | -- | -292.50K | -292.50K |
| Issuance of Common Stock | 191.80K | 191.80K | 1.12M | 1.47M | 1.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -50.00K | -267.30K |
| Cash from Financing | -15.11M | 191.80K | 1.12M | 1.13M | 813.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.85M | 14.65M | 15.51M | -8.78M | -29.79M |